KRAS and neoplasm: TP53 was the most common mutation identified in the tumor tissue of ER group, accounting for 62.5% (5/8) of the patients; K-ras and EGFR mutations were the second most common, accounting for 37.5% (3/8) of the patients.(Figure 3 and Supplementary Table 1).